Six pathogenic strains ofNaegleria fowleri, two ofAcanthamoeba castellanii, and three ofAcanthamoeba polyphaga were tested in vitro for susceptibility to a variety of potentially useful therapeutic agents. Minimal motility inhibitory concentrations and minimal inhibitory concentrations were determined by a technique of subculturing pure clones of amoebae in plastic tissue culture chamber slides containing liquid axenic media and serially diluted drug, incubating at 3000 forAcanthamoeba and at 3700 forNaegleria, and observing on an inverted microscope at 6 h for inhibition of motility and at 24 and 48 h for inhibition of growth. Drug concentrations were selected on the basis of fluid levels achievable in humans. Amphotericin B, clotrimazole, and miconazole were the most effective drugs against Naegleria, whereas polymyxin B sulfate and pentamidine isethionate were somewhat effective against pathogenicAcanthamoeba. Our results suggest that amphotericin B is the most effective agent against Naegleria, but few agents are effective against Acanthamoeba.
Not until the 1960s was the pathogenicity of free-living amoebae fully appreciated, that is, when the disease primary amoebic meningoencephalitis (PAM), an acute, rapidly fatal infection occurring in otherwise healthy humans, was recognized (3, 15) . In this disease victims are children or young adults who have been swimming in or exposed to fresh or brackish waters; the responsible pathogen is a free-living amoebo-flagellate belonging to the genus Naegleria, specifically, Naegleria fowleri (14) . Amoebae enter the nose and during the subsequent 5 to 6 days migrate through submucosal structures and nerves, ultimately invading the subarachnoid space and brain substance beneath the cribriform plate. Within 72 h rapid deterioration of the patient ensues, resulting in coma and death. An almost identical disease may be produced experimentally in mice by intranasal instillation of these same amoebae (20) .
In addition to Naegleria, within the last few years, amoebae of the genera Acanthamoeba and Hartmannella also are being increasingly incriminated as a cause of meningoencephalitis (14, 16, 23) and, in addition, as a cause ofnonfatal infections, such as ophthalmitis (21; D. B. Jones, G. S. Visvesvara, and N. M. Robinson, Oxford Ophthalmological Congress, Oxford, England, 1975) and otitis (17) . Experimental infections in mice with Acanthamoeba-Hartmannella spp. can also be produced (8, 10, 19); however, in contrast to Naegleria, when Acanthamoeba sp. are instilled intranasally, pneumonia is often the principal disease, and an incubation period longer than 7 days is usually present (19) . Spread to the central nervous system occurs principally via the blood stream and generally has resulted in chronic (occasionally granulomatous) encephalitis and minimal, if any, meningitis.
Because of the serious nature of both Naegleria and Acanthamoeba-Hartmannella infections in humans and because of an almost complete lack of therapeutic agents available against these pathogens, a variety of drugs reported or demonstrated to have antiprotozoan activity was examined. To test drug susceptibility, a liquid, bacteria-free (axenic) in vitro test system was developed and utilized ( Fig. 1 ). Agents to be studied were solubilized in stock solutions from which maximum concentrations and subsequent twofold dilutions were made in modified Nelson's axenic liquid nutrient medium (22) . The pH of this medium with and without drugs was between 7.2 and 7.4. Using an automatic nonelectric pipette (BBL 60422), 0.4 ml of each drug concentration (obtained by making twofold serial dilutions of the drug in axenic media) was placed in chambers of an eight-chambered Lab-Tek tissue culture chamber/slide (Miles Laboratories, no. 4808). Again, using the automatic non-electric pipette, 0.1-ml suspensions containing 103 trophozoites from 48-to 72-h 37°C liquid axenic cultures of Naegleria or from 30°C liquid axenic cultures of Acanthamoeba were added to each chamber. (The decision to use 103 amoebae/0. 1 ml was made to provide microscopic fields of approximately 25 to 40 organisms when a 25x ocular and lOx objective of an inverted, American Optical, ordinary light microscope were used.) To one chamber, as appropriate controls, amoebae were added to axenic media, containing, if necessary, a concentration of solvent equivalent to that used in the maximum drug concentration studied.
After incubation at either 37 or 30°C (depending on the species of amoeba being studied) for 6 h, minimal motility inhibition concentrations (MMIC) were determined by microscopic examination and comparison with controls. Immobilization of trophozoites was generally accompanied by certain morphological changes, as described previously (12) : diminution in size, rounding up, watery ectoplasm, increase in granulation, and/or complete disintegration of amoebae. The MMIC was defined as the lowest concentration of drug at which no active pseudopodial activity was seen as compared with controls. After reincubation of the chamber slide for 24 h and again for a total of 48 h, the minimal inhibitory concentration (MIC) of growth was determined. The MIC was defined as the lowest concentration of drug at which growth was 50% less than that of the control, as determined visually on the inverted microscope (Fig. 2) .
All susceptibility tests were run in triplicate (with one exception), and geometric means were calculated for the MMIC and 24- Clotrimazole and miconazole were also effective against Naegleria, but their effect was not as rapid as was that of amphotericin B. For example, mean MMICs determined 6 h after exposure to clotrimazole were 50 ,ug/ml against all six strains. In addition, concentrations required to inhibit growth varied considerably from strain to strain, as mean 24-h MICs of clotrimazole against these same strains ranged from -s0.39 ,ug/ml to as high as 39.69 ,ug/ml ( effect has been difficult to predict; i.e., too many bacteria may create an anaerobic environment, which may be inhibitory to amoebae, or too few may create a nutrient deficiency problem that may be misinterpreted as a direct inhibitory effect of the drug being tested, or the presence of bacteria or their by-products may possibly degrade or alter the test drugs being examined. However, perhaps most importantly, the presence of bacteria as a nutrient source is not comparable to the bacteria-free environment associated with the diseases produced by these organisms.
In vivo studies in mice also have indicated that amphotericin B administered in therapeutically acceptable quantities is effective in preventing PAM (4, 11) . More importantly, however, studies in humans with PAM, from whom the responsible pathogen has been isolated and known to be Naegleria, have also indicated that amphotericin B in therapeutic doses may be rapidly effective (24 to 48 h) in sterilizing the central nervous system of infecting amoebae (13) . In addition, the only cases of survival (2, 6) from culturally proven cases of PAM have been attributed to amphotericin B, the remarkable aspects of these cases being no apparent sequelae.
The precise mechanism of action of amphotericin B on Naegleria is not known; however, as a polyene, amphotericin B binds to sterols in the membrane, preferentially to ergosterol and cholesterol (1) . Schuster and Rechthand have recently shown that amphotericin B is amebicidal when used during the lag phase of amoebic growth but mainly inhibitory when used during the log phase of growth (24) . Ultrastructural changes that they observed were distortions of nuclear shape, increase in cytoplasmic membranes (both rough and smooth endoplasmic reticulum), decrease in food vacuoles, absence of pseudopods, abnormal mitochondria, increase in autophagic vacuoles, and blebbing of the plasma membrane. These investigators also observed that, with increased time of exposure to amphotericin B, these abnormalities increased, a finding supported by our studies, namely, that growth-inhibiting activity was greater after 48 h of exposure to amphotericin B than after 24 h ofexposure. Also, by using timelapse cinematography studies of pathogenic Naegleria exposed to lethal concentrations of amphotericin B, we have observed, over a period of less than 1 h, sequential rounding up (loss of pseudopods), increase in number and size of vacuoles (coalescing), development of watery cytoplasm, increased size of organisms, increased visibility of granules, and, eventually, rupturing or disintegration of the trophozoite with complete loss of contents (unpublished data).
It has been suggested in the literature that clotrimazole or some of its analogues might be used to treat PAM due to Naegleria (18) . Jamieson and Anderson, in studying a New Zealand strain of pathogenic Naegleria, observed that amebostatic activity of clotrimazole lay in the range of 0.06 to 0.12 ug/ml, and amebicidal activity is in the range of 0. 12 to 1.0 Ag/ml (18) .
Although they studied 16 human pathogens and observed a uniform amebicidal concentration of 0.15 jig/ml for an inoculum size of 730 amoebae, they also observed that such a concentration failed to prevent growth when the inoculum size was increased to 7,300 amoebae. Although we also observed that clotrimazole and miconazole inhibited growth of pathogenic Naegleria after 24 to 48 h of exposure (Table 2) , these agents did so less rapidly and with less predictability than did amphotericin B. For example, in our test system the 24-h growth of W.M., L.L., T.Y., and G.J. was inhibited in low concentrations by both clotrimazole and miconazole, but the two Australian strains (F-66 and F-69) were not. However, after 48 h of exposure to clotrimazole or miconazole, the two Australian strains finally demonstrated susceptibility. Thus, the length of time that was required for inhibition of amoebic growth by both these agents render them of less therapeutic value than amphotericin B. PAM is a disease in which rapid and, if possible, complete effect (less than 24 h) oftherapeutic agents used must occur or the patient will probably die or suffer irreversible neurological sequelae. In addition, if the results reported by Jamieson and Anderson (18) of an adverse effect of inoculum size are correct, since studies of the number of amoebae that may be present in the cerebrospinal fluid of infected patients may be in excess of 150,000 trophozoites in the subarachnoid space alone (13), clotrimazole and miconazole would not appear to be indicated to treat this disease.
In general, in vitro studies on motility inhibition (MMIC) of amoebae may be a quick and simple method of suggesting the capability of an agent not only to inhibit the growth of amoebae but, more importantly, to destroy them rapidly (12) . Amoebae depend on pseudopodial activity and motility for feeding. Such tests can be performed in any laboratory in 4 to 6 h and can offer the clinician treating the disease valuable guidance early in the course oftherapy. By studying motility 6 h after exposure, MMICs of amphotericin B appeared to reliably predict rapid cidal activity and growth inhibition. On the other hand, such studies with miconazole, because of poor motility inhibition, suggested that rapid killing did not occur, even though eventually (by 24 h) inhibition of growth was demonstrated. All other agents tested did not affect motility, and, predictably, they did not inhibit growth.
The lack of or poor susceptibility of pathogenic Acanthamoeba species to all agents tested was disturbing. Only polymyxin B and pentamidine isethionate appeared to be slightly effective, but only in concentrations that would probably be unattainable in the subarachnoid space or brain substance unless introduced intrathecally. Although the two ocular pathogens (Gresham and Garcia) demonstrated the highest resistance, it is possible that in such infections (from which these strains were isolated), ophthalmic solutions could contain concentrations approaching the 24-and 48-h MICs. It is noteworthy that amphotericin B, clotrimazole, and miconazole, although effective against Naegleria, were ineffective against Acanthamoebae. The reason(s) for this is obscure, but for amphotericin B it probably relates to differing concentrations and availability of various sterols and lipids in the membranes of such species.
The lack of susceptibility of Acanthamoeba sp. to 5-fluorocytosine is in contrast to studies by Stevens and O'Dell (25) and Casemore (7) .
Their investigations found 5-fluorocytosine to be inhibitory in a range of 12.5 (7) to >40 ,ug/ml (25); however, Stevens and O'Dell noted that virulent Acanthamoeba sp. were more resistant than avirulent ones (25) and were susceptible only at concentrations exceeding 40 ,ug/ml. The explanation for resistance of our strains of Acanthamoeba to 5-fluorocytosine is unknown but could have been: (i) due to the enriched media used by us, which probably contained small quantities of competing pyrimidines, e.g., cytosine; (ii) because most of our strains were highly pathogenic and thus inherently more resistant; or (iii) simply due to variations in technique (e.g., solvents, solubility of agents tested, dilutions, media, etc.).
